User login
Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.
Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P = .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).
Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.
Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.
Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206
Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.
Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P = .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).
Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.
Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.
Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206
Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.
Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P = .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).
Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.
Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.
Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206